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Abstract (word count: 250) 
Background: The early diagnosis of urgent abdominal pain (UAP) is challenging. Most 
causes of UAP are associated with extensive inflammation. We therefore hypothesized 
that quantifying inflammation using interleukin-6 and/or procalcitonin would provide 
incremental value in the emergency diagnosis of UAP. 
Methods: This was an investigator-initiated prospective, multicenter diagnostic study 
enrolling patients presenting to the Emergency Department (ED) with acute abdominal 
pain. Clinical judgment of the treating physician regarding the presence of UAP was 
quantified using a visual-analog-scale after initial clinical and physician-directed 
laboratory assessment, and again after imaging. Two independent specialists 
adjudicated the final diagnosis and the classification as UAP (life threatening, needing 
urgent surgery and/or hospitalization for acute medical reasons) using all information 
including histology and follow-up. Interleukin-6 and procalcitonin were measured 
blinded in a central laboratory.  
Results: UAP was adjudicated in 376/1038 (36%) patients. Diagnostic accuracy for 
UAP was higher for interleukin-6 (ROC AUC 0.80, 95%CI 0.77-0.82) versus 
procalcitonin (AUC 0.65; 95%CI 0.62-0.68) and clinical judgment (AUC 0.69; 95%CI 
0.65-0.72, both P<0.001). Combined assessment of interleukin-6 and clinical judgment 
increased the AUC at presentation to 0.83 (95%CI 0.80-0.85) and after imaging to 0.87 
(95%CI 0.84-0.89) and improved the correct identification of patients with and without 
UAP (net improvement in mean predicted probability: presentation +19%; after imaging 
+15%, P<0.001). Decision-curve-analysis documented incremental value across the 
full range of pretest probabilities. A clinical judgment/interleukin-6 algorithm ruled-out 
UAP with a sensitivity of 97% and ruled-in UAP with a specificity of 93%. 
Conclusion: Interleukin-6 significantly improves the early diagnosis of UAP in the ED.  
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Introduction 
Acute abdominal pain is the most common presenting symptom in emergency 
department (ED) patients(1-3). Its differential diagnosis is extensive and challenging(4, 
5). While 20-25% of patients require hospital admission and 10% of all episodes are 
life threatening or require urgent surgery, most episodes of acute abdominal pain are 
self-limiting and benign(3, 4, 6). Hence, rapid and accurate diagnosis of urgent causes 
of abdominal pain (UAP) is essential for the early initiation of effective therapy and 
efficient patient flow.  
Clinical assessment including patient history, detailed physical examination and 
routine laboratory testing remains the cornerstone of initial patient care(7, 8). However, 
in isolation this strategy has poor diagnostic accuracy(9, 10). Imaging techniques, 
particularly CT-scans(10, 11), are of enormous value(12) but the appropriate selection 
of patients benefiting from imaging remains an unmet clinical need. Routine CT-scans 
in all patients with acute abdominal pain would inappropriately increase the incidence 
of rare, but potentially fatal adverse events such as allergic reactions to intravenous 
contrast agents, long-term hazards related to radiation exposure, as well as inherent 
costs(13, 14). On the other hand, an overly restrictive use of CT-scans would delay the 
detection and treatment of UAP and thereby potentially increase morbidity and 
mortality.  
The incremental value of biomarkers in the early diagnosis of UAP still is 
uncertain. Based on the enormous medical and economic value provided by 
biomarkers in patients presenting to the ED with acute chest pain and acute 
dyspnea(15-21), which are supported by a Class I recommendations in current clinical 
practice guidelines(22, 23), we hypothesized that biomarkers may also be able to 
provide incremental value in patients presenting with acute abdominal pain.  
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As most causes of UAP are associated with inflammation, this study aimed to 
evaluate the incremental value of two biomarkers quantifying inflammation -interleukin-
6(24-26) and procalcitonin(27, 28)- in a large multicenter diagnostic study. 
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Methods 
Trial design and oversight 
Basel Abdominal Symptoms Evaluation Study (Basel VII) was an investigator-initiated 
prospective, international, multicenter diagnostic study enrolling unselected patients in 
six hospitals in three countries (Switzerland, Spain, Italy). The study was carried out 
according to the principles of the Declaration of Helsinki and approved by the local 
ethics committees. The authors designed the study, gathered, analyzed and report the 
data according to the STARD guidelines for studies of diagnostic accuracy (see Table 
S1 in the online Supplemental file).  
 
Patients 
To ensure the inclusion of the full spectrum of patients with acute abdominal pain, 
unselected adult patients presenting to the ED with acute non-traumatic abdominal 
pain as their main complaint were enrolled after written informed consent was obtained, 
irrespective of prior counseling by a general practitioner and triage severity(29). 
Importantly, the study investigators were not directly involved in patient care/treatment 
or the selection of imaging procedures, nor did they have any influence on the decision 
to admit or discharge patients. Patients were evaluated in the ED by at least two 
physicians not involved in the study: a resident in emergency medicine/surgery and a 
board-certified emergency medicine specialist and/or a board-certified surgeon. All 
patients underwent an initial clinical evaluation including history taking, detailed 
physical examination, standard physician-directed blood measurements and in women 
of childbearing age, a urine pregnancy test. All imaging including CT-scans, plain 
abdominal radiographs, ultrasound and magnetic resonance imaging was performed 
as clinically indicated. Clinical judgment of the treating physician regarding the urgency 
of acute abdominal pain was quantified using a visual-analog-scale (VAS) from 0 
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(benign, non-urgent abdominal pain) to 10 (UAP, life threatening, needing urgent 
(<72h) surgery and/or hospitalization for acute medical reasons) after initial clinical and 
physician-directed laboratory assessment and again after physician-directed imaging 
and serial clinical assessment when the patient was considered ready for 
admission/discharge. The treating physicians were blinded to the interleukin-6 and 
procalcitonin concentrations. 
Follow-up 
Patients were contacted by telephone 1 and 6 months after the initial ED presentation. 
Referring physicians and/or administrative databases were contacted in case of any 
remaining uncertainties regarding health status, further hospitalizations or surgeries.  
Adjudicated Final Diagnosis 
The final diagnosis and classification as UAP was centrally adjudicated by two 
independent internists/surgeons who reviewed all available medical records —clinical 
history, findings on physical examination, results of laboratory tests, radiologic studies, 
surgical interventions, histopathology reports, and follow-up data. The independent 
specialists were blinded to the interleukin-6 and procalcitonin concentrations. When 
there was disagreement about the diagnosis, cases were reviewed and adjudicated in 
conjunction with a third specialist. The final diagnosis was adjudicated in two domains: 
First, urgent versus non-urgent causes of abdominal pain; second the specific 
diagnosis causing abdominal pain. UAP was defined as life threatening, needing 
urgent (<72h) surgery and/or hospitalization for acute medical reasons (e.g. i.v. 
antibiotic therapy). Surgery and/or hospitalization per se did not define UAP. Non-
urgent causes of abdominal pain were defined as disorders not meeting these criteria.  
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Blood sampling and laboratory methods 
Blood samples for the determination of interleukin-6 and procalcitonin were collected 
in tubes containing potassium EDTA at the time of the patient`s ED presentation. 
Additional samples were obtained 3h after presentation. After centrifugation, samples 
were frozen at −80°C until assayed in a blinded fashion in a dedicated core laboratory. 
For the primary analysis, interleukin-6 and procalcitonin were measured using highly 
sensitive immunoassays based on the concept that high analytical sensitivity is critical 
for a rule-out strategy. Interleukin-6 was measured with the Erenna® immunoassay  
system (Singulex, Inc., singulex.com), which uses a micro-particle immunoassay and 
single-molecule counting in a capillary flow system. The assay’s limit of detection is 
0.01ng/L with lower and upper limits of quantification at 0.08ng/L and 50ng/L, 
respectively. Intraassay and interassay coefficents of variation were 6% and 13%, 
respectively. Procalcitonin was quantified with an automated sandwich immunoassay 
using a time-resolved amplified cryptate emission (TRACE) technology assay (PCT 
Kryptor®, B.R.A.H.M.S. GmbH, brahms.de) with a detection limit of 0.02µg/L and a 
functional assay sensitivity of 0.06µg/L according to the manufacturer. The interassay 
coefficient of variation for concentrations >0.3µg/L is <6%. Secondary analyses were 
performed to validate the robustness of this approach for routine clinical care using 
assays that run on a widely available laboratory analyzer. Detailed characteristics of 
the secondary immunoassays are described in the online Supplemental file.  
Statistical analysis 
Diagnostic uncertainty for UAP was defined as clinical judgment of 3/10 to 7/10 for an 
urgent cause. Receiver-operating-characteristic (ROC) curves were constructed to 
assess sensitivity, specificity and 95% confidence intervals of interleukin-6 and 
procalcitonin. Mean predicted probabilities for clinical judgment VAS, log-transformed 
interleukin-6 (because of non-normal distribution) and the combination of both were 
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calculated using multivariable binary logistic regression models. The comparison of 
areas under ROC curves (AUC) was performed as recommended by DeLong(30). To 
assess the incremental yield of interleukin-6 for the early diagnosis of UAP on top of 
clinical judgment, reclassification tables for net reclassification improvement (NRI) 
were used(31). Results were verified using integrated discrimination improvement (IDI) 
analysis, which is not dependent on risk groups because probability differences are 
used(31). Clinical usefulness and net benefit of interleukin-6 were estimated with 
decision-curve-analysis(32).       
 Secondary analyses included a direct comparison of the diagnostic accuracy of 
the open-label routine laboratory tests WBC and CRP (e.g. available to the clinical 
team and the adjudicating experts, thereby contributing to clinical judgment and final 
diagnosis and prone to inclusion bias) with the blinded, investigational interleukin-6 
and procalcitonin concentrations. All hypothesis testing was two-tailed, P-values <0.05 
were considered to indicate statistical significance. Cutoff values were determined 
using predefined sensitivities and specificities (70%, 80%, 90% and >95%) for UAP 
using ROC analysis. The impact of interleukin-6 groups on 30-day and 180-day 
mortality was assessed by Kaplan-Meier curves and compared by log-rank test. 
Statistical analyses were performed using SPSS for Windows 22.0 (IBM), MedCalc 
11.2.1.0. (MedCalc Software) and the R statistics package (R Foundation for Statistical 
Computing). 
 
Results 
Patient characteristics 
Patient flow is shown in Figure S1 in the online Supplemental file. From October 2009 
to January 2012, 1150 patients were recruited and 1038 patients were available for the 
primary analysis (Table 1). Diagnostic uncertainty of the treating physician regarding 
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UAP was present in 58% of patients after initial clinical and laboratory assessment and 
in 49% after imaging, when the patient was considered ready for admission/discharge 
(Figure S2). Overall, 1343 imaging studies were performed in 887 patients (Table 2). 
The need for imaging was higher in UAP patients than in patients with non-urgent 
causes of abdominal pain (94% vs 81%, p<0.001). In UAP patients abdominal 
ultrasound (173, 46%) and abdominal CT (150, 40%) were the most frequently 
performed imaging procedures.  The median time interval from ED presentation until 
patients were considered ready for admission/discharge was 329 minutes.  
Adjudicated final diagnosis 
The adjudicated final diagnosis was UAP in 376 (36%) patients; urgent surgery was 
necessary in 217 (58%), hospitalization in 128 (34%) and a non-surgical urgent 
intervention in 31 (8%) UAP patients. The specific diagnoses causing acute abdominal 
pain are described in the online Supplemental results (Table S2).  
Diagnostic accuracy of interleukin-6 and procalcitonin at presentation  
Interleukin-6 and procalcitonin plasma concentrations were significantly higher in 
patients with UAP compared to patients with non-urgent causes (interleukin-6: median 
23.3ng/L [IQR: 8.7-77.7] vs. 4.4ng/L [2.1-10.9], P<0.001; procalcitonin: 0.10µg/L [0.07-
0.27] vs. 0.07µg/L [0.05-0.10], p<0.001). (Table 2; Figure S3). The frequency of 
findings on clinical examination and their respective diagnostic accuracies are 
described in the supplemental results (Table S3).  
Diagnostic accuracy for UAP, as quantified by the AUC was significantly higher 
for interleukin-6 (0.80; 95%CI 0.77-0.82) compared to procalcitonin (0.65, 95%CI 0.62-
0.68, P<0.001; Figure S4) and initial clinical judgment (0.69; 95%CI 0.66-0.73, 
P<0.001). In IDI analysis, interleukin-6 adequately decreased the mean predicted 
probability of UAP in patients with non-urgent pain by 6% and increased the mean 
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predicted probability by 10% in patients with UAP compared to clinical judgment alone 
(net improvement in mean predicted probability +16%, P<0.001).  
The AUC for interleukin-6 significantly also exceeded the AUCs for open-label 
WBC (0.74; 95%CI 0.71-0.77, P=0.001) and CRP (0.73, 95%CI 0.70-0.77, P<0.001; 
Figure S5).  
Early incremental value 
Combined assessment of interleukin-6 at presentation and initial clinical judgment 
(AUC 0.83, 95%CI 0.80-0.85) significantly improved the diagnostic accuracy over initial 
clinical judgment alone (AUC 0.69, 95%CI 0.66-0.73; P<0.001, Figure 1). The NRI of 
the additional use of interleukin-6 compared to initial clinical judgment alone (Table 3) 
amounted to 27.3% (P<0.001). In patients with non-urgent abdominal pain, 111 
patients (16.7%) correctly moved downward and 23 (3.5%) incorrectly moved upward 
in the classification. In patients with urgent abdominal pain, 85 patients (22.6%) 
correctly moved upwards and 32 (8.5%) incorrectly moved downward in the 
classification. The combined use of interleukin-6 and initial clinical judgment, improved 
the correct identification of patients with and without UAP in IDI analysis (net 
improvement in mean predicted probability +19%, P<0.001) compared to clinical 
judgment alone. Interleukin-6 provided incremental clinical usefulness in addition to 
clinical judgment over the full range of probability thresholds (i.e. increased number of 
true positives predictions without increasing the number of false positive predictions, 
Figure 2). Exemplified, in a patient clinically judged to have a low probability of urgent 
abdominal pain (VAS2/10), using the combined model identified 169 more true 
positives per 1000 patients without an increase in false positive predictions compared 
to the VAS alone. In a patient clinically judged to have a medium to high risk of urgent 
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abdominal pain (VAS8/10) the combined model identified 56 more true positives per 
1000 patients without increase in false positive predictions compared to the VAS alone.  
 
Late incremental value 
The combined assessment of interleukin-6 at presentation and final clinical judgment 
after imaging when the patient was considered ready for admission/discharge (AUC 
0.87, 95%CI 0.84-0.89) continued to significantly improved the diagnostic accuracy 
over final clinical judgment alone (P<0.001, Figure S6). The NRI of the additional use 
of interleukin-6 compared to final clinical judgment alone amounted to 28.0% 
(P<0.001).  
Similarly, the combined use of interleukin-6 and final clinical judgment improved 
the correct identification of patients with and without UAP in IDI analysis (net 
improvement in mean predicted probability +15%, P<0.001) compared to final clinical 
judgment. Again, interleukin-6 provided incremental clinical usefulness in addition to 
clinical judgment over the full range of probability thresholds (Figure S7).  
Combined triage algorithm 
Figure 3 displays an early triage algorithm combining clinical assessment and 
interleukin-6 concentrations. In short, interleukin-6 concentrations below 2.4ng/L ruled-
out 197 patients (20%) with a sensitivity of 97% and a negative likelihood ratio of 0.11 
for UAP. The diagnostic characteristics of interleukin-6 at pre-specified sensitivity and 
specificity target levels (Table S4) are described in the online Supplemental file. Eight 
patients (8/376 UAP patients; 2%) were incorrectly classified by the combined triage 
algorithm are summarized in Table S5.  
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Serial sampling  
A second interleukin-6 measurement after 3 hours did not improve the diagnostic 
accuracy provided by interleukin-6 at presentation (AUC for combination 0.79, 95%CI 
0.76-0.82, P=0.47). 
Subgroups  
Results from pre-specified subgroup analyses are described in the Supplemental 
results.  
 
Prognostic performance of interleukin-6  
There were 4 deaths during the initial hospitalization and 27 deaths in the whole cohort 
within 180 days. Survival at 30 days (P=0.002) and 180 days (P=0.031) was 
significantly associated with interleukin-6 concentrations (Figure S8). Cumulative 
survival rates were 100%, 99.5% and 97.4% at 30 days and 98.6%, 96.1 and 91.4% 
at 180 days, respectively. The hazard ratio for the risk of death within 180 days was 
4.2 (95%CI 1.1-15.9, P=0.034) for patients in the rule-in group as compared with 
patients in the rule-out group. Similarly, 30-day survival was 100% in patients triaged 
towards rule-out by the combined clinical/interleukin-6 algorithm. The cause of death 
was cancer in 15 patients (8 primarily extraabdominal, 7 primarily intrabdominal), 
cardiovascular in 3 patients, UAP in 2 patients and unknown in 7 patients dying at 
home. Of the four patients dying during the initial hospitalization 2 patients died of UAP 
and 2 patients died of primarily extraabdominal cancers.  
Secondary analysis 
Measurements of interleukin-6 and procalcitonin on a large automated analyzer 
revealed similar findings compared to the primary analysis (online Supplemental file).  
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Discussion 
This prospective, multicenter diagnostic study examined interleukin-6 and procalcitonin 
plasma concentrations for the early diagnosis of UAP. We report seven major findings: 
First, the diagnostic accuracy of the initial clinical assessment of acute abdominal pain 
was only modest and significantly inferior to the diagnostic accuracy of initial clinical 
assessment for the two other common presenting symptoms to the ED: acute dyspnea 
and acute chest pain(33, 34). Diagnostic uncertainty of the treating physician regarding 
an urgent cause of abdominal pain was present in 58% of patients after initial clinical 
and laboratory assessment and in 49% after imaging, when the patient was considered 
ready for admission/discharge. Second, the diagnostic accuracy of interleukin-6 was 
significantly superior to initial clinical judgment, procalcitonin and the open-label routine 
blood parameters WBC and CRP. Third, interleukin-6, but not procalcitonin, provided 
incremental diagnostic value to both initial and final clinical judgment and significantly 
increased the diagnostic accuracy. The additional use of interleukin-6 significantly 
improved the adequate detection of patients with non-urgent abdominal pain (rule-out) 
as well as the identification of UAP patients (rule-in). Decision-curve-analysis 
documented incremental value and clinical usefulness across the full range of pretest 
probabilities. Fourth, the combined use of clinical judgment and interleukin-6 
concentrations allowed the development of a rapid triage algorithm to assign patients 
towards rule-out or rule-in of UAP. In 197 (20%)  patients with a low to intermediate 
clinical probability for an urgent cause of acute abdominal pain (e.g. VAS<8/10) 
interleukin-6 concentrations below 2.4ng/L ruled-out UAP with a sensitivity of 97%, 
similar to the sensitivity of CT-angiography in the rule-out of pulmonary embolism(35). 
The immediate consequence of triage towards rule-out will be considering early 
discharge from the ED and outpatient management. A high clinical probability for an 
urgent cause of acute abdominal pain (e.g. VAS>8/10) or interleukin-6 concentrations 
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above 63.5ng/L ruled-in UAP in 176 patients (17%) with a specificity of 93%. The high 
specificity for an urgent cause of acute abdominal pain in the rule-in group justifies 
early CT-imaging and/or surgical consultation as the immediate consequence of triage 
towards rule-in. Fifth, 30-day survival was 100% in patients triaged towards rule-out, 
highlighting the suitability of many of these patients for early discharge and outpatient 
management. Sixth, the diagnostic accuracy of interleukin-6 was consistent in various 
pre-specified subgroups. Seventh, secondary analyses using measurements of 
interleukin-6 and procalcitonin performed on a widely available automated large 
analyzer showed similar results and thereby provided internal validation of our findings. 
In addition, it documents the immediate availability of this novel strategy in clinical 
practice.  
These findings extend and corroborate previous research on the clinical use of 
biomarkers in acute abdominal pain(24-27). Small single-center pilot studies recruiting 
selected patients with right iliac fossa pain suggested that interleukin-6 and 
procalcitonin concentrations might act as disease severity markers with higher levels 
being associated with a need for surgery(24-27).  
Importantly, although interleukin-6 does substantially improve the emergency 
diagnosis of UAP, its concentrations should always be interpreted in conjunction with 
all other clinically available information. This is highlighted by the combined 
interpretation of clinical assessment and interleukin-6 concentrations achieving the 
best diagnostic accuracy at every diagnostic step in the present study. In addition, the 
release of interleukin-6 seems to be time-dependent. Accordingly, repeat 
measurements may be considered in interleukin-6 negative early patients presenting 
very early after the onset of acute abdominal pain, although our data could not show a 
significant difference.  
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The most important non-urgent disease entity to consider in interleukin-6 
positive patients is irritable bowel syndrome (IBS). A recent small pilot study highlighted 
increased interleukin-6 serum concentrations in patients with IBS as diagnosed by the 
Rome III criteria(36). Similarly, 10 of the 29 patients with a non-urgent cause of 
abdominal pain and interleukin-6 concentrations >63.50ng/L suffered from non-specific 
abdominal pain, which is strongly associated with the IBS(37).  
The most important urgent entity to be considered in patients incorrectly ruled-
out by the combined triage algorithm appears to be persistent biliary colic. In fact, 2 of 
the 4 patients with persistent biliary colic were clinically judged to have a low to 
intermediate clinical probability for an urgent cause of acute abdominal pain and 
presented with interleukin-6 concentrations below 2.4ng/L. The need for endoscopic 
retrograde cholangiopancreatography (ERCP) in the setting of choledocholithiasis is 
dictated by persistent biliary pain, obstructive jaundice, cholangitis, pancreatitis, or any 
combination thereof. While the interleukin-6 positive patient presented with clinically 
apparent jaundice, the ERCP indication was based on persistent pain in all triage 
algorithm negative patients, which in itself does not seem to induce an acute phase 
response. Also, 3 of 91 (3%) patients suffering from acute appendicitis were incorrectly 
ruled-out by the combined triage algorithm. 
Acute abdominal pain may also occasionally be caused by acute life-threatening 
extra-abdominal disorders, such as acute myocardial infarction. Accordingly, these 
disorders were classified as urgent in this study. However, our findings should not be 
misinterpreted as suggesting the use of interleukin-6 plasma concentrations in the 
work-up of patients, in whom, e.g., acute myocardial infarction is suspected. If an acute 
life-threatening extra-abdominal disorder is suspected, established standard operating 
procedures for its safe rule-out(23) should be strictly adhered to irrespective of 
interleukin-6 concentrations.  
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Current guidelines for the assessment of acute abdominal pain(7, 8) call for an 
early blood draw in all patients with potentially urgent abdominal pain. Our data suggest 
that interleukin-6 should be considered for inclusion in this laboratory panel. Used in 
conjunction with all clinically available information, interleukin-6 could simplify the 
allocation of patients to imaging and/or surgical evaluation (rule-in pathway), additional 
medical work-up of differential diagnoses and early clinical reappraisal (observe), or 
rapid discharge and outpatient management (rule-out pathway). 
The current study has several limitations. First, while the multicenter design 
should blunt local differences in referral patterns, diagnostic work-ups, and health care 
systems, and thereby allows the generalization of these findings to EDs, the 
generalizability of our findings to other settings, e.g. primary care, remains unknown. 
Second, as this was not an intervention study, we cannot assess the effect of 
interleukin-6 guided triage on clinical management, patient outcome and its cost-
effectiveness. While an open-label randomized controlled management trial will surely 
provide important additional information, a diagnostic study with blinded 
measurements and central adjudication of the final diagnosis provides more precise 
estimates of the incremental value of novel diagnostic tests(16, 19). It is likely that more 
rapid and more accurate rule-out using interleukin-6 will reduce time to discharge and 
treatment costs in the ED(15, 20).  
In conclusion, interleukin-6 concentrations significantly improve the early 
diagnosis of patients presenting with acute abdominal pain to the ED. Use of an 
Interleukin-6-based early triage algorithm has the potential to provide substantial 
medical and economic value.  
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Table 1. Baseline 
characteristics   
 
Final adjudicated diagnosis 
 
 
Overall  
(N=1038)  
Non-urgent pain 
(N=662)  
Urgent pain  
(N=376) 
P-
Value* 
Age, yrs. 49 +19  47 +19  53 +19 <.001 
Sex, male 531 (51)  320 (48)  211 (56) .030 
Symptoms          
Duration of Pain , h 18  [7-58]  20 [6-69]  17 [7-48] .176 
Acute onset of pain 
(within minutes) n pat (%) 457 (44) 
 287 (43)  170 (45) .106 
Worsening pain, n (%) 460  (44)  271  (41)  189 (50) .010 
Co-morbidities          
BMI, kg/m2 24.9 [22.0-28.4]  24.8  [21.8-28.4]  25.2 [22.5-28.1] .202 
Diabetes 78 (8)  46 (7)  32 (9) .394 
Hypertension 233 (22)  129 (20)  104 (28) .004 
Cardiac Disease 98 (9)  44 (7)  54 (14) <.001 
Hepatic disease  64 (6)  39 (6)  25 (7) .689 
Diverticulosis 56 (5)  24 (4)  32 (9) .001 
Neoplastic disease 61 (6)  34 (5)  27 (7) .218 
Clinical examination at  
presentation   
 
  
 
   
Distended abdomen 70 (7)  41 (6)  29 (8) .170 
Localized tenderness 829 (80)  512 (77)  317 (84) .024 
Localized rebound 
tenderness  232 (22) 
 103 (16)  129 (34) <.001 
Localized guarding 180 (17)  71 (11)  109 (29) <.001 
Vital signs          
Systolic blood pressure, 
mmHg 135 [120-148] 
 135 [120-149]  134 [121-148] .682 
Diastolic blood pressure, 
mmHg 79 [70-87] 
 79 [70-88]  78 [69-86] .148 
Heart rate, bpm 80 [70-93]  79 [69-89]  84 [72-99] <.001 
Body Temperature, °C 36.7 [36.2-37.2]  36.6 [36.2-37.1]  36.9 [36.3-37.4] <.001 
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Routine Laboratory 
Parameters    
       
Hemoglobin, g/l 142 [131-153]  142 [131-152]  142 [130-154] .647 
White blood count, G/l 9.4 [7.1-12.6]  8.3 [6.5-10.5]  12.0 [9.2-15.4] <.001 
Creatinine, umol/l 68 [57-82]  68 [57-81]  70 [59-85] .038 
AST, U/l# 25 [20-32]  24 [20-31]  25 [20-33] .033 
Alkaline phosphatase, U/l 69 [57-87]  68 [56-83]  71 [57-94] .005 
Pancreatic amylase, U/l 28 [20-44]  29 [21-44]  27 [18-45] .052 
C-reactive protein, mg/l 6.1 [2.2-37.7]  4.9 [1.6-14.9]  27.5  [4.9-93.2] <.001 
Values are mean ± SD, number (percentage) and median [interquartile range]. *P-Value for 
differences between groups. # AST, aspartate aminotransferase 
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Table 2. Clinical judgment, imaging 
and Biomarker results Overall  
(N = 1038) 
 
Non-urgent pain 
(N=662) 
 
Urgent pain  
(N=376) P-Value* 
Clinical judgement          
ED Clinical VAS (x/10) 4.0 [2.0-6.0]  3.0  [2.0-5.0]  6.0 [3.0-7.0] <.001 
ED Conclusion VAS (x/10) 4.0 [2.4-6.5]  3.0 [1.8-5.0]  6.5 [4.2-8.0] <.001 
ED Resources          
Need for imaging, n pat (%) 887 (86)  533 (81)  354 (94) <.001 
Plain abdominal X-ray, n pat (%) 355 (34)  234 (35)  121 (32) 0.315 
Abdominal ultrasound, n pat (%) 386 (37)  213 (32)  173  (46) <.001 
Abdominal CT, n pat (%) 283 (27)  131 (20)  152 (40) <.001 
Chest/upper abdomen CT, n pat (%) 15 (1)  7 (1)  8 (2) 0.182 
Abdominal MRI, n pat (%) 9  (1)  3 (1)  6 (2) 0.079 
Plain Chest X-ray, n pat (%) 295 (28)  169 (25)  126 (33) 0.006 
Number of imaging modalities  1.41 ±0.87  1.41 ±0.88  1.67 ±1.07 <.001 
Treatment time in ED, min 329 [209-581]  276 [190-458]  460  [276-758] <.001 
Biomarker          
Erenna Interleukin-6,  ng/L 7.4 [2.9-4.6]  4.4 [2.1-10.9]  23.3 [8.7-77.7] <.001 
Elecsys Interleukin-6,  ng/L 5.7 [1.5-21.8]  2.2 [1.5-9.9]  20.7  [7.1-72.3] <.001 
Kryptor Procalcitonin, µg/L 0.08 [0.05-0.13]  0.07 [0.05-0.10]  0.10  [0.07-0.27] <.001 
Elecsys Procalcitonin,  µg/L 0.02 [0.02-0.05]   0.02  [0.02-0.03]  0.03  [0.02-.0.11] <.001 
Values are mean ± SD, number (percentage) and median [interquartile range]. ED denotes Emergency 
Department; *P-Value for differences between groups.  
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Table 3 
Reclassification of patients with and without urgent abdominal pain by Erenna 
Interleukin-6 
 
Patients with non-urgent abdominal pain 
 
ED Initial Clinical Judgment  
Clinical Judgment & Interleukin-6 
Total Low probability  Observe High probability  
  Low probability  
(VAS < 3/10) 
266 1 6 273 
Uncertainty  
(VAS 3/10-7/10) 
91 243 16 350 
High probability  
(VAS >7/10) 
6 14 19 39 
Total 363 258 41 662 
 
 
Patients with urgent abdominal pain 
 
ED Initial Clinical Judgment  
Clinical Judgment & Interleukin-6 
Total Low probability Observe High probability 
  Low probability  
(VAS < 3/10) 
57 1 13 71 
Uncertainty  
(VAS 3/10-7/10) 
9 158 71 237 
High probability  
(VAS >7/10) 
3 20 45 68 
Total 68 179 129 376 
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Figure Legends:  
Figure 1: Receiver-operating-characteristic (ROC) curves showing the diagnostic 
accuracies of initial clinical judgment after patient history, clinical examination and 
routine laboratory tests and its combination with interleukin-6 for the diagnosis of 
urgent abdominal pain.  
Figure 2: Decision curve analysis of combined use of blinded interleukin-6 and initial 
ED clinical judgment versus clinical judgment alone for the diagnosis of urgent 
abdominal pain. Assume all without urgent abdominal pain - all patients have a 
predicted probability of 0.0. Assume all with urgent abdominal pain - all patients have 
a predicted probability of 1.0. ED Clinical VAS - patients have a predicted probability 
based on initial clinical judgment after patient history, clinical examination and routine 
laboratory tests. Combination Interleukin-6/ED Clinical VAS - patients have a predicted 
probability based initial clinical judgement and its combination with interleukin-6  
Figure 3: Algorithm for the early diagnosis of urgent abdominal pain combining initial 
clinical judgment and interleukin-6 concentrations in patients presenting with acute 
abdominal pain. 0h indicates Interleukin-6 at presentation to the ED 
 
 
 
